When will the BENTYL PRESERVATIVE FREE patents expire, and when will BENTYL PRESERVATIVE FREE go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	BENTYL PRESERVATIVE FREE	dicyclomine hydrochloride	INJECTABLE;INJECTION	008370-002	Oct 15, 1984		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 1, 2026

Bentyl Preservative Free is the injectable formulation of dicyclomine hydrochloride, an anticholinergic used for functional bowel and irritable bowel syndrome symptoms. Its investment profile is driven by generic injectable economics, hospital supply reliability, manufacturing compliance, and contract access rather than patent exclusivity. The product has no identifiable long-term composition-of-matter moat, no meaningful FDA exclusivity period, and limited differentiation beyond preservative-free presentation, route of administration, and supply availability.

What is Bentyl Preservative Free?

Bentyl Preservative Free is dicyclomine hydrochloride injection, generally supplied as a 20 mg/2 mL single-dose presentation for intramuscular administration. The product is intended for short-term use when oral dicyclomine is impractical. The FDA labeling states that the injection should be administered intramuscularly and not intravenously because of the risk of thrombosis, thrombophlebitis, or injection-site injury.[1]

Attribute	Product profile
Brand name	Bentyl
Active ingredient	Dicyclomine hydrochloride
Drug class	Anticholinergic, antispasmodic
Common injectable strength	20 mg/2 mL
Route	Intramuscular
Dosage form	Injectable solution
Preservative status	Preservative-free single-dose presentation
Primary use	Functional bowel and irritable bowel syndrome symptoms
FDA pathway	Small-molecule drug approval; generic ANDA pathway applicable
Biologic status	Not a biologic; biosimilar analysis does not apply
Patent position	Legacy active ingredient with no meaningful modern composition-of-matter protection
Main commercial buyers	Hospitals, emergency departments, outpatient facilities, wholesalers, group purchasing organizations

The injectable formulation has a narrower market than oral dicyclomine capsules, tablets, or solution. Its value is concentrated in institutional settings where parenteral administration is required or where preservative-free packaging is preferred.

What patents protect Bentyl Preservative Free?

No meaningful active patent estate is expected to protect the dicyclomine active ingredient or the core Bentyl injectable formulation. Dicyclomine was developed and commercialized decades ago, placing the original compound and foundational therapeutic claims well beyond the standard 20-year U.S. patent term.

The relevant protection categories are:

Protection category	Investment relevance
Composition-of-matter patent	Expired or commercially irrelevant
Basic method-of-use patent	Expired or commercially irrelevant
Injectable formulation patent	No apparent durable exclusivity identified for the core product
Device patent	Not material for a conventional vial or ampule presentation
Manufacturing patent	Possible process know-how, but unlikely to block ordinary ANDA competition
Regulatory exclusivity	No meaningful current exclusivity expected
Trademark	Bentyl brand rights may remain commercially relevant but do not prevent generic dicyclomine sales

A generic manufacturer generally does not need to overcome a durable patent barrier to enter the dicyclomine injection market. The principal legal work is likely to involve ANDA requirements, labeling, chemistry and manufacturing controls, facility compliance, and any listed patents appearing in the FDA’s current Orange Book database.[2]

Is Bentyl Preservative Free protected by Orange Book patents?

The commercial risk profile indicates little or no Orange Book patent protection of practical importance. Orange Book listings must be checked against the specific reference-listed drug and dosage form because FDA databases can change as products are approved, discontinued, or transferred between applicants.[2]

For investment analysis, the absence of a material patent barrier has three consequences:

A competitor can pursue approval through the ANDA pathway rather than a costly 505(b)(2) strategy.
A Paragraph IV patent challenge is unlikely to be the central entry mechanism if no blocking patent remains listed.
Any pricing advantage depends on supply, quality, distribution, and contracting rather than exclusivity.

When does Bentyl lose exclusivity?

Bentyl’s meaningful exclusivity has already expired. The product is a legacy small-molecule drug, and its commercial position is not based on current new-drug exclusivity.

Exclusivity category	Status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance
New formulation exclusivity	No established durable exclusivity for the preservative-free injection
Patent exclusivity	No meaningful remaining composition-of-matter protection
Generic exclusivity	Depends on any specific approved ANDA and Paragraph IV history

FDA’s generic-drug framework allows applicants to rely on the safety and efficacy findings for the reference product, subject to bioequivalence and quality requirements.[3] Injectable products can face more demanding chemistry, manufacturing, and controls review than simple oral products because sterility, container closure, particulate matter, endotoxin control, and process validation directly affect approval and supply continuity.

What is the FDA regulatory status of Bentyl Preservative Free?

The product is regulated as a prescription small-molecule drug. Its regulatory value is tied to an established FDA label and an existing clinical-use history rather than novel clinical data.

Key labeling restrictions affect market use:

The injection is for intramuscular administration.
Intravenous administration is contraindicated.
The injectable form is generally used for short-term treatment.
Oral therapy is preferred when the patient can take medication by mouth.
Anticholinergic adverse effects include dry mouth, blurred vision, dizziness, constipation, urinary retention, and tachycardia.
Serious risks include heat prostration, particularly in hot environments, and worsening of certain gastrointestinal or urinary conditions.[1]

The product is not interchangeable with every dicyclomine presentation on a simple unit-for-unit basis. Oral capsules, tablets, oral solution, and injectable products have different administration requirements and clinical-use settings.

How many patents cover Bentyl Preservative Free?

The commercially relevant number is effectively zero for blocking core-product patents. Any residual patents would more likely involve a specific manufacturing process, packaging configuration, or later-developed delivery technology rather than the basic dicyclomine injectable product.

This distinction matters. A process patent may increase manufacturing complexity without preventing a competitor from using a different process. A packaging patent may affect one presentation but not the active ingredient. Neither type typically creates the same barrier as a valid composition-of-matter patent.

Patent strength can be assessed as follows:

Patent factor	Assessment
Scope	Narrow if limited to process or packaging
Remaining term	Unlikely to provide meaningful long-term protection
Design-around risk	High
ANDA vulnerability	High
Litigation leverage	Low
Commercial moat	Minimal

What formulation patents protect the preservative-free injection?

The principal technical differentiation is the preservative-free injectable presentation. That differentiation does not automatically create patent protection. A preservative-free product may be defined by formulation composition, container closure, sterilization method, or stability profile, but those characteristics can be difficult to defend unless supported by a valid and non-obvious patent claim.

The manufacturing barriers are more important than the patent barriers:

Sterile compounding and aseptic processing
Validated sterilization or sterile filtration
Low particulate burden
Container-closure integrity
Stability through labeled shelf life
Control of endotoxins and bioburden
Reliable supply of vials, ampules, or other primary containers
FDA-compliant manufacturing facilities

A company with an established sterile injectables platform may have a cost and reliability advantage even when it has no patent advantage. That advantage can disappear after a manufacturing warning letter, recall, inspection failure, or raw-material disruption.

Which companies are challenging Bentyl Preservative Free?

Competition is expected to come primarily from manufacturers of generic dicyclomine hydrochloride injection rather than from branded pharmaceutical innovators. Relevant competitive groups include:

Generic injectable manufacturers with ANDA portfolios.
Hospital-focused suppliers with sterile manufacturing capacity.
Contract manufacturers that can produce dicyclomine injection for a marketing applicant.
Wholesalers and private-label suppliers that compete through distribution and contracting.
Manufacturers of alternative antispasmodic or gastrointestinal products.

The competitive set can change quickly because injectable products are frequently affected by discontinuations, site transfers, and supply interruptions. FDA’s Drugs@FDA database, the Orange Book, and FDA drug-shortage resources are the primary sources for current approval and availability checks.[2,4]

What generic entry risks exist for Bentyl Preservative Free?

Generic entry risk is high because the product has:

An old active ingredient
No meaningful composition-of-matter barrier
Established FDA safety and efficacy information
A conventional injectable presentation
Limited product differentiation
A small but identifiable institutional market

The main constraint is not legal entry. It is the economics of sterile injectable manufacturing.

Generic launch scenarios

Scenario	Market effect	Probability profile
One reliable generic supplier	Stable but concentrated supply; moderate pricing pressure	Commercially plausible
Two or more approved suppliers	Lower prices and weaker margins	High long-term risk
Supplier discontinuation	Temporary price recovery and shortage-driven demand	Recurring industry risk
Manufacturing failure	Short-term scarcity, backorders, and contract repricing	Material operational risk
Hospital conversion to oral therapy	Structural reduction in injection demand	Moderate
New preservative-free competitor	Limited differentiation and price erosion	Plausible

An investor should not treat a shortage as evidence of durable market power. Shortages can raise near-term revenue while exposing the manufacturer to regulatory scrutiny, expedited competition, and hospital substitution.

What patent litigation affects Bentyl Preservative Free?

No major patent litigation appears central to the product’s current investment case. The expected legal exposure is more likely to involve:

ANDA approval disputes
Product liability claims
Manufacturing or sterility-related recalls
Contract disputes with distributors or group purchasing organizations
Trademark use involving the Bentyl name
FDA inspection or compliance actions

A Paragraph IV challenge would matter only if an applicable patent were listed for the relevant reference product and dosage form. Given the age of dicycline and the absence of a clear blocking patent estate, litigation-based delay is unlikely to provide a durable commercial advantage.

What is the commercial market for Bentyl Preservative Free?

The injectable market is smaller than the oral dicyclomine market and is concentrated in acute-care and institutional channels. Demand depends on clinical preference, hospital formularies, emergency-department protocols, and availability of oral administration.

Revenue drivers

Number of available sterile injectable suppliers
Hospital contract wins
Wholesaler inventory levels
GPO participation
Product shortages among competitors
Average selling price per vial or ampule
Conversion from injectable to oral therapy
FDA compliance record
Manufacturing yield and batch-release reliability

Revenue constraints

Limited use duration
Substitution by oral dicyclomine
Low clinical differentiation
Generic pricing pressure
Small patient population requiring injection
Hospital purchasing concentration
High sterile-manufacturing overhead
Potential anticholinergic safety limitations

Revenue exposure should be modeled by channel rather than by total dicyclomine prescriptions. Oral products may generate substantially greater volume, while injectable products can produce higher gross-margin volatility because of shortages and constrained supply.

How strong is the patent estate for Bentyl Preservative Free?

The patent estate is weak. The product can have commercial value without having patent value, but that value is operational and contractual.

Investment dimension	Rating	Rationale
Patent protection	Low	Legacy active ingredient and limited apparent blocking IP
Regulatory barrier	Moderate	Sterile injectable approval and quality requirements
Manufacturing barrier	Moderate to high	Aseptic production, validation, and facility compliance
Pricing power	Low	Generic competition and limited differentiation
Shortage upside	Moderate	Supply interruptions can support temporary pricing
Long-term growth	Low	Narrow indication and mature market
Litigation protection	Low	Limited basis for exclusionary patent enforcement
Supply-chain risk	High	Sterile injectable manufacturing is interruption-sensitive
Licensing value	Low to moderate	Mainly manufacturing, distribution, or regional rights

Are there licensing deals for Bentyl Preservative Free?

Licensing value is more likely to arise from commercial arrangements than from proprietary patent rights. Potential structures include:

Regional marketing rights
Supply agreements with sterile injectable manufacturers
Private-label arrangements
Hospital and GPO contracts
Co-development of an improved container or delivery system
Portfolio licensing involving several generic injectables

A standalone license for Bentyl Preservative Free would have limited strategic value unless it includes reliable manufacturing capacity, regulatory approvals in multiple jurisdictions, or access to a broader institutional product portfolio.

How does Bentyl Preservative Free compare with oral dicyclomine?

Factor	Preservative-free injection	Oral dicyclomine
Primary setting	Hospitals and acute care	Outpatient and chronic symptom management
Administration	Intramuscular	Capsule, tablet, or oral solution
Demand	Narrower	Broader
Manufacturing complexity	High due to sterility	Lower
Patent moat	Minimal	Minimal
Generic competition	Limited by sterile capacity	Broad
Substitution risk	High from oral products	Lower within outpatient use
Shortage sensitivity	High	Moderate
Commercial value	Supply-dependent	Volume-dependent

The injectable product may command a premium during shortages, but oral dicyclomine is the more scalable market because it serves a larger outpatient population and has lower manufacturing costs.

Does biosimilar risk apply to Bentyl Preservative Free?

No. Dicyclomine hydrochloride is a synthetic small molecule, not a biologic. Competitors enter through generic-drug approval pathways rather than biosimilar applications under the Public Health Service Act.

This eliminates the scientific comparability and interchangeability issues associated with monoclonal antibodies, insulin products, and other biologics. Competitive risk instead centers on pharmaceutical equivalence, bioequivalence where applicable, sterile manufacturing, labeling, and facility compliance.[3]

What geographic coverage applies to Bentyl Preservative Free?

U.S. rights depend on FDA approval, the applicable reference-listed drug, and the marketing status of each applicant. Patent conclusions in the United States do not establish freedom to operate elsewhere.

Region	Main commercial issue
United States	ANDA approval, Orange Book status, sterile manufacturing, hospital contracts
European Union	National or centralized marketing authorization requirements; different reference-product framework
Canada	Health Canada submission and drug-identification requirements
Emerging markets	Local registration, pricing controls, and tender access
Contract-manufacturing jurisdictions	GMP compliance and export authorization

The strongest geographic advantage would come from an established multi-region sterile injectables network, not from dicycline patent rights.

What is the investment scenario for Bentyl Preservative Free?

Base case

The base case is a mature, low-growth generic injectable with limited pricing power. Revenue remains dependent on hospital contracts and dependable supply. Margins are acceptable if the manufacturer has efficient sterile capacity and low regulatory risk.

Upside case

The upside case depends on a competitor’s discontinuation, a shortage, or a supply disruption that permits temporary price increases. A portfolio owner may also create value by bundling the product with other hospital injectables and improving contract utilization.

Downside case

The downside case involves new generic entry, hospital conversion to oral therapy, a failed inspection, a recall, or a loss of a major wholesaler or GPO contract. Because the product has little patent protection, there is no long-term exclusion period to absorb competitive shocks.

Investment conclusion

Bentyl Preservative Free is better analyzed as a supply-chain and generic-manufacturing asset than as an intellectual-property asset. Its risk-adjusted value depends on sterile production reliability, market concentration, contract tenure, and shortage conditions. A high valuation based on patent exclusivity or branded-drug economics would be difficult to justify. A lower valuation supported by manufacturing capability, stable institutional contracts, and a broader injectable portfolio may be defensible.

Key Takeaways

Bentyl Preservative Free is an injectable dicyclomine hydrochloride product, generally supplied at 20 mg/2 mL for intramuscular use.
The active ingredient and core therapeutic claims are legacy assets with no meaningful remaining composition-of-matter protection.
The Orange Book patent position is unlikely to create a durable barrier to generic entry.
Paragraph IV litigation is not expected to be the central commercial risk.
Biosimilar competition does not apply because dicyclomine is a small molecule.
Sterile manufacturing, FDA compliance, supply continuity, and hospital contracting are more important than patents.
The product has limited long-term growth but can generate temporary upside during shortages.
Oral dicyclomine is a broader and more scalable market, while the injection has higher operational complexity.
Licensing value is primarily tied to manufacturing and distribution rights.
The appropriate investment thesis is operational, not IP-driven.

FAQs

Is Bentyl Preservative Free still a branded product?

Bentyl is the historical brand associated with dicyclomine. The injectable product competes in a market dominated by generic-drug economics, and the brand name alone does not create patent-based exclusivity.

Can a generic company launch dicyclamine injection without a Paragraph IV challenge?

Yes. If no applicable blocking patent is listed for the relevant reference product, an applicant can pursue an ANDA without using a Paragraph IV certification as the principal entry strategy.

Why can a generic injectable retain value after patent expiration?

Sterile manufacturing capacity, regulatory compliance, hospital contracts, and supply reliability can restrict effective competition even when legal entry is open.

Is preservative-free packaging a strong competitive moat?

Usually not by itself. It may support customer preference or specific institutional use, but it becomes a durable moat only if protected by enforceable formulation, container, or manufacturing claims.

What would most improve the investment case?

The strongest improvements would be reliable sterile capacity, multi-year institutional contracts, low recall exposure, a diversified injectable portfolio, and evidence that competitors face persistent supply constraints.

References

U.S. Food and Drug Administration. (2023). Bentyl (dicyclomine hydrochloride injection) prescribing information. FDA. https://www.accessdata.fda.gov
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/
U.S. Food and Drug Administration. (2024). Generic drugs: Questions and answers. FDA. https://www.fda.gov/drugs/questions-answers/generic-drugs
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for BENTYL PRESERVATIVE FREE